Tandem Diabetes Care's 15min chart shows RSI Oversold, KDJ Golden Cross.

Tandem Diabetes Care's 15-minute chart has triggered an RSI oversold signal and a KDJ golden cross at 08/06/2025 13:45. This indicates that the stock price has declined rapidly and fallen below its fundamental support level, suggesting a shift in momentum towards an upward trend. As such, the stock has the potential to continue increasing in value.

Title: Tandem Diabetes Care (TNDM) Stock: Technical Indicators Signal Potential Upside

Tandem Diabetes Care, Inc. (TNDM) has recently experienced a significant drop in its stock price, as indicated by the 15-minute chart triggering an RSI oversold signal and a KDJ golden cross on August 6, 2025, at 13:45. These technical indicators suggest a shift in momentum towards an upward trend, suggesting that the stock could continue to increase in value.

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. An RSI reading below 30 is typically considered oversold, indicating that the stock may be undervalued and ripe for a rebound. The KDJ golden cross occurs when the K line crosses above the D line, signaling a potential trend change from bearish to bullish.

Tandem Diabetes Care reported a quarterly loss of $0.48 per share in the second quarter of 2025, which was a slight improvement compared to the Zacks Consensus Estimate of $0.4 per share [1]. Despite the loss, the company's revenues of $240.68 million for the quarter ended June 2025 surpassed the Zacks Consensus Estimate by 0.87% [1].

The stock has lost about 57.9% since the beginning of the year, compared to the S&P 500's gain of 7.1% [1]. This underperformance has raised concerns among investors about the company's future prospects. However, the recent technical indicators suggest that the stock may be poised for a rebound.

Investors should also consider the company's earnings outlook and the industry's performance. The Zacks Rank #2 (Buy) for Tandem Diabetes Care indicates that the stock is expected to outperform the market in the near future [1]. The Medical - Instruments industry, however, ranks in the bottom 41% of the 250 plus Zacks industries, which could impact the stock's performance [1].

Pacific Biosciences of California (PACB), another stock in the same industry, is expected to post a quarterly loss of $0.18 per share in its upcoming report, representing a year-over-year change of +10% [1]. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Tandem Diabetes Care has a consensus rating of Hold from analysts, with an average rating score of 2.33 and a forecasted upside of 127.3% from its current price of $20.59 [2]. The stock has been the subject of strong analyst interest, with 5 research reports in the past 90 days.

The company's insiders have been buying more of their stock than they have sold in the past three months, with $21,450.00 in company stock bought and $0.00 sold [2]. Only 2.50% of the stock is held by insiders [2].

While the technical indicators suggest a potential upward trend, investors should remain cautious and conduct thorough research before making any investment decisions. The company's earnings outlook, industry performance, and analyst ratings should all be considered when evaluating Tandem Diabetes Care as a potential investment.

References:
[1] https://www.nasdaq.com/articles/tandem-diabetes-care-inc-tndm-reports-q2-loss-beats-revenue-estimates
[2] https://www.marketbeat.com/stocks/NASDAQ/TNDM/